Tackling Healthcare Disparities for Historically Overlooked Patients With Multiple Myeloma | Webcast

1.00 AMA PRA Credits
Overview
Learning Objectives
CME/ Information
Faculty and Disclosures

Program Overview

Racial and ethnic disparities in multiple myeloma (MM) impact outcomes, with Black patients facing higher incidence, poorer survival, and less access to advanced treatments. Many healthcare providers lack awareness of these inequities and the importance of culturally competent shared decision-making (SDM). Educational programs focused on SDM, cultural competence, and team-based care are essential to reduce disparities and improve outcomes for all MM patients.

Target Audience

This educational program is directed toward hematologists/oncologists in both the academic and community setting as well as advanced practice providers and other HCPs involved in the management of patients with MM. 

Supporter Acknowledgement

This educational activity is supported by independent educational grants from GSK and Janssen Biotech, Inc administered by Janssen Scientific Affairs, LLC.

Learning Objectives

Upon completion of this activity, the participant should be able to:
  • DESCRIBE racial and ethnic factors in patients with MM that affect incidence, disease characteristics, progression, and patient survival.
  • IDENTIFY disparities in MM care and access to novel treatments among underserved populations.
  • OUTLINE treatment plans incorporating collaborative SDM that address social and cultural norms, health literacy needs, and build trust in the patient-clinician relationship.
  • IMPLEMENT team-based strategies to mitigate healthcare disparities in MM, focusing on equitable access to emerging therapies and patient-centered care.

Accredited Provider

This activity is jointly provided by Global Education Group and Iridium Continuing Education.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosures of Relevant Financial Relationship(s)

​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Joseph Mikhael, MD, Med, FRCPC, FACP, FASCO
Professor, Translational Genomics Research Institute - City of Hope Cancer Center,
Chief Medical Officer - International Myeloma Foundation
Consulting Fee (e.g., Advisory Board):
Amgen, BMS, Janssen, Menarini, Sanofi
Jorge Monge Urrea, MD
Assistant Professor of Medicine, University of Colorado
Consulting Fee (e.g., Advisory Board):
Johnson & Johnson, Pfizer
Dan Sherbenou, MD, PhD
Consulting Fee (e.g., Advisory Board):

Kelly Sidor, MSN
ACNP-BC
Consulting Fee (e.g., Advisory Board):

This educational activity is supported by independent educational grants from GSK and Janssen Biotech, Inc administered by Janssen Scientific Affairs, LLC.

Activity Credit Amount: 1.00

Credit Type: ACCME, ANCC
Release: 03/31/2025
Expiration: 03/31/2026